pocketful logo light
pocketful logo light
Jagsonpal Pharmaceuticals Ltd logo

Jagsonpal Pharmaceuticals Ltd

NSE: JAGSNPHARM BSE: 507789

236.54

(1.52%)

Sun, 23 Aug 2026, 08:36 am

Jagsonpal Pharmaceuticals Share Price Live Chart

1 Day

(1.52%)

No Result Found

Summary

  • Market Cap (in Cr)

    1352.73

  • Net Profit (in Cr)

    55.36

  • P/B

    5.99

  • Sector P/E

    44.89

  • P/E

    25.89

  • EV/EBITDA

    16.65

  • Debt/Equity (Industry)

    0.24

  • Interest Cover (Industry)

    9.79

  • ROCE (Industry)

    14.04

  • RONW (Industry)

    13.17

  • ROE

    18.58

  • ROCE

    22.82

  • Debt/Equity

    0.04

  • EPS (TTM)

    6.81

  • Dividend Yield

    1.98

  • Book Value

    42.10

  • Interest Cover

    53.26

Analysis

all

thumbs up icon

Pros

  • Dividends paid are thoroughly covered by earnings (14.2x coverage).
  • Jagsonpal Pharmaceuticals's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
  • Jagsonpal Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Jagsonpal Pharmaceuticals is profitable, therefore cash runway is not a concern.
  • Jagsonpal Pharmaceuticals is profitable, therefore cash runway is not a concern.
thumbs up icon

Cons

  • No dividend growth in 10 years.
  • Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
  • Jagsonpal Pharmaceuticals's dividend is below the markets top 25% of dividend payers in India (3.08%).
  • High level of physical assets or inventory.
  • Jagsonpal Pharmaceuticals is not covered by any analysts.

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters67.8967.3967.5467.6567.78
FII2.442.122.122.182.10
DII0.220.150.090.050.00
Public29.4530.3430.2530.1230.11
Government00000

Read More

Technical Analysis

RSI

56.96

MACD

1.66

50 DMA

227.97

200 DMA

201.87

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic335.17285.71258.25236.25208.79186.79137.33
Fibonacci285.71266.81255.14236.25217.35205.68186.79
Camarilla244.40239.87235.33236.25226.27221.73217.20

Pivots Level: Classic

R3

+98.92

335.17

R2

+49.46

285.71

R1

+22.01

258.25

236.25
236.25
Pivot Point
LTP: 236.54

S1

-27.45

208.79

S2

-49.46

186.79

S3

-98.92

137.33

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    232.14

  • 20-EMA

    231.07

  • 30-EMA

    229.63

  • 50-EMA

    225.84

  • 100-EMA

    217.50

  • 200-EMA

    212.01

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
27 Apr 2026board-meetingsAccounts, Final Dividend
12 Mar 2026buyback
21 Jan 2026board-meetingsQuarterly Results
03 Nov 2025board-meetingsQuarterly Results
12 Aug 2025dividendFinal Dividend - Rs. - 2.512 Sept 2025
26 Jul 2025agm
06 May 2025dividend₹2.50 Dividend /Share12 Sept 2025
08 Dec 2024splitStock Split From Rs.5 to Rs.208 Jan 2025
08 Dec 2024dividendFace Value Split (Sub-Division) - From Rs 5/- Per Share To Rs 2/- Per Share08 Jan 2025
23 Oct 2024split1:2.5 Splits of Equity Shares08 Jan 2025

Read More

Peer Comparison

Jagsonpal Pharmaceuticals Ltd logo

Jagsonpal Pharmaceuticals Ltd

Cipla Ltd logo

Cipla Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Read More

Jagsonpal Pharmaceuticals Ltd About

Jagsonpal Pharmaceuticals engaged in the business of manufacturing and trading of pharmaceutical products and active pharmaceutical ingredients.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1978

Headquarters

CEO

Harsha Raghavan

Employees

Contact

Website icon

Website

http://www.jagsonpal.com

Email icon

Email

skmata@jagsonpal.com; cs@jagsonpal.com

Phone icon

Phone

91-011-46181100/46109900

Location icon

Location

T-210 J, Shahpur Jat, New Delhi, New Delhi, 110049

Read More

Jagsonpal Pharmaceuticals Ltd Company History

YearHistory
No Result Found

Read More

Deals

Client NameDeal TypeOrder SideQTYAvg PriceDate
HRTI PRIVATE LIMITEDbulkSell343628293.528 Jul 2025
GRAVITON RESEARCH CAPITAL LLPbulkBuy498300293.6828 Jul 2025
GRAVITON RESEARCH CAPITAL LLPbulkSell498300294.128 Jul 2025
HRTI PRIVATE LIMITEDbulkBuy350647293.5628 Jul 2025
ANKITA VISHAL SHAHbulkSell154425779.5429 Nov 2024
ANKITA VISHAL SHAHbulkBuy249425775.1729 Nov 2024
INFINITY PORTFOLIO HOLDINGSblockBuy220000040013 Sept 2024
INFINITY PORTFOLIO HOLDINGSbulkBuy220000040013 Sept 2024
INFINITY HOLDINGSblockSell220000040013 Sept 2024
INFINITY HOLDINGSbulkSell220000040013 Sept 2024

Read More

Jagsonpal Pharmaceuticals Ltd News

Jagsonpal Pharma Q1 FY27 Earnings Call Recording Available

Jagsonpal Pharmaceuticals Limited has made the audio recording of its Q1 FY27 earnings conference call available on its website, held on July 30, 2026.

30 Jul 2026

companies

Jagsonpal Pharma names two senior executives

Jagsonpal Pharmaceuticals Ltd designates Balmukund Keshav and Sanjay Singhal as Senior Management Personnel effective July 29, 2026, following internal restructuring.

29 Jul 2026

companies

Jagsonpal Pharma Sets Dividend Record Date

Jagsonpal Pharmaceuticals fixes September 4, 2026, as the record date for a proposed dividend of Rs 4 per share, pending AGM approval.

29 Jul 2026

companies

Jagsonpal Pharma Q1FY26: Profit up 22% YoY

Jagsonpal Pharmaceuticals reported a 22% YoY rise in net profit to ₹131.89 million for Q1FY26, driven by an 8.8% revenue increase. The firm also acquired an 85% stake in Aequitas Healthcare.

29 Jul 2026

companies

Jagsonpal Pharmaceuticals to host Q1FY27 earnings call

Jagsonpal Pharmaceuticals will hold an analyst conference call on July 30, 2026, to discuss its Q1 FY27 financial results. The call is scheduled for 2:30 PM IST.

22 Jul 2026

companies

Read More

Open Your Free Demat Account

Enter your phone number